Search clinical trials for: ZD 1839

Total 122 results

Niiki Pharma Inc.

Completed

Dose Escalation Study of NKP-1339 to Treat Advanced Solid Tumors

Solid Tumors

United States
Stanford University
AstraZeneca; American Society of Clinical Oncology

Completed

Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck

Head and Neck Cancer | Carcinoma, Squamous Cell

United States
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer

Insular Thyroid Cancer | Recurrent Thyroid Cancer | Stage IIIB Non-small Cell Lung Cancer | Anaplastic Thyroid Cancer | Tongue Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous... and other conditions

United States
University of Chicago

Completed

Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer

Head and Neck Cancer

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma

United States
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Bronchoalveolar Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

Gastrinoma | Glucagonoma | Insulinoma | Metastatic Gastrointestinal Carcinoid Tumor | Pancreatic Polypeptide Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | WDHA Syndrome

United States
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Malignant Mesothelioma

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma

United States
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery

Stage IIIA Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Bronchoalveolar Cell Lung Cancer | Large Cell Lung Cancer | Adenosquamous Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer

Canada
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Brigham...

Completed

Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer

Metastatic Pancreatic Carcinoma

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast

Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Children With Refractory Solid Tumors

Unspecified Childhood Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer

Squamous Cell Carcinoma of the Skin | Recurrent Skin Cancer

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma

United States
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca

Completed

Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas

Gastric Cancer | Esophageal Cancer

United States, Puerto Rico
National Cancer Institute (NCI)

Terminated

Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Stage III Squamous Cell Carcinoma of the Hypopharynx | Stage III Squamous Cell Carcinoma of the Larynx | Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage III Squamous Cell Carcinoma of the Oropharynx | Stage IV Squamous Cell Carcinoma of the Hypopharynx | Stage IV Squamous... and other conditions

United States
National Cancer Institute (NCI)

Completed

Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer

Esophageal Cancer

United States
National Cancer Institute (NCI)

Terminated

Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer

Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer

United States
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma

United States
Shanghai Haiyan Pharmaceutical Technology Co.,...

Recruiting

Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder

Insomnia Disorder

China
National Cancer Institute (NCI)

Completed

Gefitinib and Capecitabine in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Five Prime Therapeutics, Inc.
Parexel

Completed

Safety Study of FP-1039 To Treat Cancer

Advanced Cancer

United States
Shanghai Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Five Prime Therapeutics, Inc.
Worldwide Clinical Trials

Withdrawn

Study of FP-1039 in Subjects With Endometrial Cancers

Endometrial Cancers With FGFR2 Mutations
Neuralstem Inc.

Unknown

A Longitudinal Observational Cohort Study of NSI-189, With Out-Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Shanghai Hengrui Pharmaceutical Co., Ltd.

Completed

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Study in Healthy Subjects

Asthma

China
Atridia Pty Ltd.

Completed

A Trial of SHR-1819 in Healthy Subjects

Healthy Volunteers

Australia
Theravance Biopharma

Completed

Multiple Ascending Dose Study of TD-1439 in Healthy Adult and Elderly Subjects

Healthy Adults, Elderly Subjects

United States
Theravance Biopharma

Completed

Single Ascending Dose Study of TD-1439 in Healthy Subjects

Healthy Subjects

United States
Merck Sharp & Dohme LLC

Completed

A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Doravirine (MK-1439) (MK-1439-019)

HIV-1 Infection
Shandong Suncadia Medicine Co., Ltd.

Recruiting

A Trial of HRS-1893 in Healthy Volunteers and Patients With Obstructive Hypertrophic Cardiomyopathy

Obstructive Hypertrophic Cardiomyopathy

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Enrolling by invitation

A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis

Moderate to Severe Atopic Dermatitis

China
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ACT-1004-1239 in Healthy Male Subjects

Healthy

United States
Neuralstem Inc.

Unknown

Study of NSI-189 for Major Depressive Disorder

Major Depressive Disorder

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Bronchoalveolar Cell Lung Cancer | Large Cell Lung Cancer | Adenosquamous Cell Lung Cancer

United States
Calithera Biosciences, Inc

Completed

A Comparative, Pharmacokinetic Study of CB-839 Capsule and Tablet Formulations in Healthy Adults

Healthy Volunteers

United States
Idorsia Pharmaceuticals Ltd.

Completed

Study in Healthy Subjects to Examine the Safety and Tolerability of ACT-1004-1239 Given as Multiple, Gradually Increasing Doses and to Examine the Effects of ACT-1004-1239 on the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-1004-1239

Healthy

Portugal
Merck Sharp & Dohme LLC

Completed

A Study Evaluating the Pharmacokinetics of Doravirine (MK-1439) in Participants With Severe Renal Impairment (MK-1439-051)

Renal Impairment
Shanghai Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE SUBCUTANEOUS INJECTIONS OF SHR-1819 IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Moderate to Severe Atopic Dermatitis
National Cancer Institute (NCI)

Completed

Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter

United States
AstraZeneca

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis

Psoriasis

Australia, New Zealand
AstraZeneca

Completed

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

Crohn's Disease

United States, Australia
Quintessence Biosciences, Inc.

Unknown

A Study of QBI-139 in Subjects With Advanced Solid Tumors

Solid Tumors

United States
National Cancer Institute (NCI)

Completed

Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Bronchoalveolar Cell Lung Cancer | Large Cell Lung Cancer

United States
Neuralstem Inc.

Completed

Single-Dose Pharmacokinetics (PK) Study of Novel Neurogenic Compound NSI-189

Depression

United States
ModernaTX, Inc.
Biomedical Advanced Research and Development Authority

Completed

Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults

Zika Virus

United States, Puerto Rico
Dongzhimen Hospital, Beijing
Tianjin University of Traditional Chinese Medicine

Recruiting

Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke (EXPECT)

Acute Ischemic Stroke

China

Search clinical trials for: ZD 1839

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Greece

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations